Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Vectura

Biotech & Life Sciences · Chippenham, United Kingdom · Founded 1997 · IPO 2008 Unicorn

Inhaled drug-device combination product development and manufacturing

Valuation
$393M
Market cap · 2026
Revenue
$252M
Latest reported FY
EBITDA
$73M
Latest reported FY

Investors

2 investors on Vectura's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 1 investor entered at this stage
Excalibur Fund Managers
Series B+ 1 investor entered at this stage
University of Bath

Global footprint

Where Vectura has talent and traffic

Workforce by country
5 countries with
team presence
🇬🇧 United Kingdom94.3%
🇨🇭 Switzerland2.7%
🇫🇷 France1.3%
🇺🇸 United States1%
🇮🇪 Ireland0.7%
5 countries shown
Web traffic by country
650 monthly visits
across markets
🇬🇧 United Kingdom92.3%
🇳🇴 Norway15.4%
Top 2 markets shown

Patent intelligence

$208M patent portfolio · 99 active families

Estimated portfolio value
$208M
52.9% of market cap · comparable to top peer Arvinas ($223M)
99 active patent families
Where Vectura innovates InhalationMedicinePhospholipidDrugInhalation Devices

Where Vectura concentrates vs peers

Each axis is a top-10 topic across Vectura and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Vectura's 3 investments and acquisitions.

Every disclosed deal where Vectura appeared as a backer or acquirer, 2014–2021. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

3 deals across Vectura's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        02 · Portfolio market map

        Vectura's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        3 of 3 deals

        Market sentiment

        What the market is saying about Vectura

        An AI-synthesized read of the highest-engagement posts about Vectura on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Vectura on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.